Ascendis Pharma Endocrinology Division A/S - CVR: 32323537

2021, EUR

09.05.2022

Bruttoresultat

-190''

Primær drift

-190''

Årets resultat

-206''

Aktiver

55.415'

Kortfristede aktiver

32.762'

Egenkapital

-715''

Afkastningsgrad

-343 %

Soliditetsgrad

-1290 %

Likviditetsgrad

+500%

Resultat

09.05.2022

Årsrapport	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017	2015 09.05.2016
Nettoomsætning
Bruttoresultat	-189.944.253	-86.451.578	-98.477.366	-89.300.964	-54.429.523	-57.341.190	-42.307.040	-28.800.471
Resultat af primær drift	-190.155.124	-86.977.449	-98.595.407	-89.421.569	-54.525.654	-57.444.235	-42.485.553	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	14	37.536	24.024	0	0	0	545	1.425
Finansieringsomkostninger	-15.766.122	-12.175.698	-9.152.094	-6.758.278	-4.633.932	-2.879.889	-1.608.998	-718.891
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	-205.921.232	-99.115.611	-107.723.477	-96.179.847	-59.159.586	-60.324.124	-44.094.006	-29.643.526
Resultat	-205.626.348	-98.887.391	-107.518.319	-95.044.994	-59.159.586	-60.324.124	-44.006.494	-29.557.717
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

09.05.2022

Årsrapport	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017	2015 09.05.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	14.256.993	12.609.399	17.528.026	9.999.028	14.646.056	9.796.383	3.643.440	5.272.094
Likvider	18.505.415	7.865.747	7.174.393	886	2.200.195	2.540.181	10.685	79.233
Kortfristede aktiver	32.762.408	20.475.146	24.702.419	9.999.914	16.846.251	12.336.564	3.654.125	5.351.327
Immaterielle aktiver og goodwill	0	0	0	0	0	0	11.185	22.370
Finansielle anlægsaktiver	22.504.232	22.504.232	17.410.923	17.410.923	17.410.923	0	0	0
Materielle aktiver	148.150	244.550	1.924.283	393.644	323.240	121.461	0	0
Langfristede aktiver	22.652.382	22.748.782	19.335.206	17.804.567	17.734.163	121.461	11.185	22.370
Aktiver	55.414.790	43.223.928	44.037.625	27.804.481	34.580.414	12.458.025	3.665.310	5.373.697

Aktiver

09.05.2022

Passiver

09.05.2022

Årsrapport	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017	2015 09.05.2016
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	-714.823.251	-509.196.903	-410.309.512	-302.791.193	-207.746.199	-148.586.613	-88.262.489	-44.255.995
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	0	0	0	0	0	0	0	0
Kortfristede forpligtelser	29.877	3.015.716	6.919.318	7.228.195	5.628.752	5.560.590	4.066.803	4.428.612
Gældsforpligtelser	770.238.041	552.420.831	454.347.137	330.595.674	242.326.613	161.044.638	91.927.799	49.629.692
Forpligtelser	770.238.041	552.420.831	454.347.137	330.595.674	242.326.613	161.044.638	91.927.799	49.629.692
Passiver	55.414.790	43.223.928	44.037.625	27.804.481	34.580.414	12.458.025	3.665.310	5.373.697

Passiver

09.05.2022

Nøgletal

09.05.2022

Årsrapport	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017	2015 09.05.2016
Afkastningsgrad	-343,1 %	-201,2 %	-223,9 %	-321,6 %	-157,7 %	-461,1 %	-1.159,1 %	Na.
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	28,8 %	19,4 %	26,2 %	31,4 %	28,5 %	40,6 %	49,9 %	66,8 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-1.206,1 %	-714,4 %	-1.077,3 %	-1.323,1 %	-1.176,7 %	-1.994,7 %	-2.640,5 %	Na.
Soliditestgrad	-1.290,0 %	-1.178,0 %	-931,7 %	-1.089,0 %	-600,8 %	-1.192,7 %	-2.408,0 %	-823,6 %
Likviditetsgrad	109.657,6 %	678,9 %	357,0 %	138,3 %	299,3 %	221,9 %	89,9 %	120,8 %

Resultat

09.05.2022

Gæld

09.05.2022

Årsrapport

09.05.2022

Nyeste:01.01.2021- 31.12.2021(offentliggjort: 09.05.2022)

Information om virksomhedens regnskabsklasse:The Annual Report of Ascendis Pharma Endocrinology Division A/S for 2021 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B. The accounting policies applied remain unchanged from last year. The Financial Statements for 2021 are presented in EUR.

Beretning

09.05.2022

Dato for ledelsens godkendelse af årsrapporten:2023-02-24

Oplysning om usædvanlige forhold:The COVID-19 pandemic has affected countries where we are operating, where we have planned or have ongoing clinical trials, and where we rely on third-parties to manufacture preclinical, clinical and commercial supply. While COVID-19 had an impact on how we work and conduct our activities, we have managed to avoid significant disruptions to our clinical and manufacturing operations. As a result of governmental restrictions, field-based sales personnel primarily have worked under a remote engagement model with healthcare professionals and patient care organizations, and similarly, some patients have not been able to see their physicians. As restrictions cease, field-based sales personnel have begun in person engagements when interacting with healthcare professionals and patient care organizations, as well as patients having easier access to their physicians. The impact on the commercial product revenue is uncertain and difficult to quantify. We monitor the risks from the pandemic closely, and work with relevant stakeholders to avoid and limit disruptions, and to develop and establish working measures. However, while COVID-19 continues to impact global societies, the uncertainty related to the duration and direction of the pandemic makes the future impact from COVID-19, including the magnitude of any impact on our operational results, highly uncertain and unpredictable.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Executive Board and Board of Directors have today considered and adopted the Annual Report of Ascendis Pharma Endocrinology Division A/S for the financial year 1 January - 31 December 2022.